Table 2. Summary of studies reporting salvage surgery (part 2).
| Authors (year) | RFS after salvage surgery | OS after salvage surgery | OS from definitive CRT | Site of recurrence after salvage surgery | Favorable prognostic factor in salvage surgery | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (months) | 3-year rate | 5-year rate | Median (months) | 3-year rate | 5-year rate | Median (months) | 3-year rate | 5-year rate | |||||
| Bauman (2008) (1) | 12 (PFS) | 39%† (PFS) | 20%† (PFS) | 30 | 47% | 24%† | N/A | N/A | N/A | L: 8%, D: 25%, L+D: 13% | N/A | ||
| Yang (2015) (3) | 10 | 31%† | 23% | 33 | 42%† | 31% | N/A | N/A | N/A | L: 13%, D: 23%, L+D: 6% | Pathological CR | ||
| Dickhoff (2016) (13) | 44 (EFS) | 66%† (EFS) | 44%† (EFS) | 46 | 68%† | 46%† | N/A | N/A | N/A | D: 13%, L+D: 7% | N/A | ||
| Shimada (2016) (14) | Not reached† | 72% | 55%† | Not reached† | 78% | 78%† | N/A | N/A | N/A | L: 17%, D: 11%, L+D: 6% | N/A | ||
| Sawada (2017) (15) | N/A | N/A | N/A | Not reached† | 75%† | 75% | Not reached† | 75%† | 75%† | L: 13% | N/A | ||
| Casiraghi (2017) (2) | 12‡ (DFS) | 20%‡ (DFS) | 20%‡ (DFS) | 13 | 32% | 20% | N/A | N/A | N/A | N/A | Long interval from definitive CRT to salvage surgery (continuous variable) | ||
| Schreiner (2018) (16) | 22 | 44%† | 44% | 30 | 46% | 46% | N/A | N/A | N/A | L: 38%, D: 38% | N/A | ||
| Sonobe (2019) (4) | 13† | 49%† | 49% | 48† | 67%† | 51% | 75† | 77%† | 61% | D: 45% | Pathological CR in conversion setting | ||
| Vielva (2019) (17) | 15 (DFS) | 9%† (DFS) | 9%† (DFS) | 76 | 58% | 53% | N/A | N/A | N/A | L: 15%, D: 30% | Radiological downstaging of T factor | ||
†, we summarized the median survival period, 3-year survival rate, and 5-year survival rate of each study, and if there was no description about these values in their own references, an author (AH) calculated these values from the Kaplan-Meier curve of each study; ‡, DFS data missing for five patients; seven patients who had explorative surgery were excluded. RFS, recurrence-free survival; OS, overall survival; PFS, progression-free survival; EFS, event-free survival; DFS, disease-free survival; CRT, chemoradiotherapy; N/A, not available; L, locoregional recurrence; D, Distant recurrence; CR, complete response.